These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

404 related articles for article (PubMed ID: 22361345)

  • 1. Use of intravenous immunoglobulin to treat chronic bilateral otomastoiditis in the setting of rituximab induced hypogammaglobulinemia.
    Otremba MD; Adam SI; Price CC; Hohuan D; Kveton JF
    Am J Otolaryngol; 2012; 33(5):619-22. PubMed ID: 22361345
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks.
    Cohen SB; Emery P; Greenwald MW; Dougados M; Furie RA; Genovese MC; Keystone EC; Loveless JE; Burmester GR; Cravets MW; Hessey EW; Shaw T; Totoritis MC;
    Arthritis Rheum; 2006 Sep; 54(9):2793-806. PubMed ID: 16947627
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inflammation and autoantibody markers identify rheumatoid arthritis patients with enhanced clinical benefit following rituximab treatment.
    Lal P; Su Z; Holweg CT; Silverman GJ; Schwartzman S; Kelman A; Read S; Spaniolo G; Monroe JG; Behrens TW; Townsend MJ
    Arthritis Rheum; 2011 Dec; 63(12):3681-91. PubMed ID: 22127691
    [TBL] [Abstract][Full Text] [Related]  

  • 4. B-cell therapies in established rheumatoid arthritis.
    Leandro MJ; Becerra-Fernandez E
    Best Pract Res Clin Rheumatol; 2011 Aug; 25(4):535-48. PubMed ID: 22137923
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Persistent hypogammaglobulinemia in an ITP patient following treatment with rituximab].
    Toubi E
    Harefuah; 2012 Nov; 151(11):620-1, 655. PubMed ID: 23367731
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial.
    Emery P; Fleischmann R; Filipowicz-Sosnowska A; Schechtman J; Szczepanski L; Kavanaugh A; Racewicz AJ; van Vollenhoven RF; Li NF; Agarwal S; Hessey EW; Shaw TM;
    Arthritis Rheum; 2006 May; 54(5):1390-400. PubMed ID: 16649186
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Safety of rituximab in patients with rheumatoid arthritis].
    Morović-Vergles J
    Reumatizam; 2010; 57(2):158-60. PubMed ID: 21875022
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does rituximab aggravate pre-existing hypogammaglobulinaemia?
    Diwakar L; Gorrie S; Richter A; Chapman O; Dhillon P; Al-Ghanmi F; Noorani S; Krishna MT; Huissoon A
    J Clin Pathol; 2010 Mar; 63(3):275-7. PubMed ID: 20203231
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rituximab for the treatment of rheumatoid arthritis: an update.
    Mok CC
    Drug Des Devel Ther; 2013 Dec; 8():87-100. PubMed ID: 24403823
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of rituximab in patients with rheumatoid arthritis refractory to disease modifying antirheumatic drugs and anti-tumor necrosis factor-alpha treatment.
    Higashida J; Wun T; Schmidt S; Naguwa SM; Tuscano JM
    J Rheumatol; 2005 Nov; 32(11):2109-15. PubMed ID: 16265687
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rituximab for the treatment of rheumatoid arthritis.
    Bagust A; Boland A; Hockenhull J; Fleeman N; Greenhalgh J; Dundar Y; Proudlove C; Kennedy T; Moots R; Williamson P; Dickson R
    Health Technol Assess; 2009 Sep; 13 Suppl 2():23-9. PubMed ID: 19804686
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis.
    Edwards JC; Szczepanski L; Szechinski J; Filipowicz-Sosnowska A; Emery P; Close DR; Stevens RM; Shaw T
    N Engl J Med; 2004 Jun; 350(25):2572-81. PubMed ID: 15201414
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and effectiveness of rituximab in patients with rheumatoid arthritis following an inadequate response to 1 prior tumor necrosis factor inhibitor: the RESET Trial.
    Haraoui B; Bokarewa M; Kallmeyer I; Bykerk VP;
    J Rheumatol; 2011 Dec; 38(12):2548-56. PubMed ID: 21965646
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characteristics of late onset neutropenia in rheumatologic patients treated with rituximab: a case review analysis from a single center.
    Besada E; Koldingsnes W; Nossent J
    QJM; 2012 Jun; 105(6):545-50. PubMed ID: 22301823
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety of biologic therapy in rheumatoid arthritis and other autoimmune diseases: focus on rituximab.
    Fleischmann RM
    Semin Arthritis Rheum; 2009 Feb; 38(4):265-80. PubMed ID: 18336874
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy in Poland].
    Samborski W; Buczek J; Bednarek A; Lewandowicz J; Kucharz E
    Pol Merkur Lekarski; 2010 Dec; 29(174):365-8. PubMed ID: 21298986
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rituximab infusion-related adverse event rates are lower in patients with systemic lupus erythematosus than in those with rheumatoid arthritis.
    Conti F; Ceccarelli F; Perricone C; Alessandri C; Conti V; Massaro L; Truglia S; Spinelli FR; Spadaro A; Valesini G
    Rheumatology (Oxford); 2011 Jun; 50(6):1148-52. PubMed ID: 21278072
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunoglobulin G replacement for the treatment of infective complications of rituximab-associated hypogammaglobulinemia in autoimmune disease: a case series.
    Roberts DM; Jones RB; Smith RM; Alberici F; Kumaratne DS; Burns S; Jayne DR
    J Autoimmun; 2015 Feb; 57():24-9. PubMed ID: 25586449
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Subcutaneous immunoglobulin in lymphoproliferative disorders and rituximab-related secondary hypogammaglobulinemia: a single-center experience in 61 patients.
    Compagno N; Cinetto F; Semenzato G; Agostini C
    Haematologica; 2014 Jun; 99(6):1101-6. PubMed ID: 24682509
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytomegalovirus colitis and hypo-IgG after rituximab therapy for rheumatoid arthritis.
    Vallet H; Houitte R; Azria A; Mariette X
    J Rheumatol; 2011 May; 38(5):965-6. PubMed ID: 21532065
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 21.